Donald Tashkin
Pulmonary Disease · Los Angeles, CANPI 1528088135
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Mylan Specialty L.p. at 38.0% of the total. Reporting peaked in 2019 at $61,827 and has fallen 74.8% since, to $15,583 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $878.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$54K
- Boehringer Ingelheim$28K
- Merck$18K
- AstraZeneca$15K
- Mylan Inc.$14K
- Sunovion Pharmaceuticals Inc.$8K
- plus $4K from 4 others
What the payments were for
- Consulting fees$46,31433%
- Speaking & faculty fees$82,40658%
- Travel & lodging$9,7367%
- Food & beverage$2,9072%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 95 | $53,744 |
| Boehringer Ingelheim | 15 | $27,818 |
| Merck | 9 | $18,483 |
| AstraZeneca | 18 | $15,350 |
| Mylan Inc. | 2 | $14,000 |
| Sunovion Pharmaceuticals Inc. | 11 | $7,566 |
| GSK | 1 | $3,250 |
| Boehringer Ingelheim International GmbH | 1 | $564 |
| Sanofi | 8 | $465 |
| Grifols USA, LLC | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$52,356
- OFEV$18,145
- Wixela Inhub$8,750
- STIOLTO RESPIMAT$8,532
- LONHALA MAGNAIR$7,330
- FASENRA$6,543
- SYMBICORT$5,812
- NUCALA$3,250
- SPIRIVA$1,545
- Prolastin-C$125
How this compares
$141,364 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Jameel HouraniLos Angeles$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.